Literature DB >> 7929028

B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.

M de Weers1, G S Brouns, S Hinshelwood, C Kinnon, R K Schuurman, R W Hendriks, J Borst.   

Abstract

X-linked agammaglobulinemia (XLA) is an inherited human immunodeficiency disease, characterized by an arrest in B-cell development, which results in a dramatic decrease in immunoglobulin production. The gene product defective in XLA has been identified as a cytoplasmic protein tyrosine kinase, named Bruton's tyrosine kinase (Btk). The dramatic XLA phenotype indicates a critical role for Btk in the regulation of B-cell development. However, neither external stimuli leading to Btk activation nor any of its in vivo substrates have thus far been identified, and the mechanism of disease induction remains unexplained. We report here that stimulation of the B-cell antigen receptor (membrane immunoglobulin) on mature B-cells induces tyrosine phosphorylation of Btk in vivo, accompanied by an increase in its kinase activity in vitro. These results place Btk in the B-cell receptor signal transduction pathway, which is known to be essential in driving B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929028

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies.

Authors:  S Nisitani; R M Kato; D J Rawlings; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.

Authors:  M I Wahl; A C Fluckiger; R M Kato; H Park; O N Witte; D J Rawlings
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 3.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Leuk Lymphoma       Date:  2012-12

Review 4.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

5.  B-cell-specific demethylation of BTK, the defective gene in X-linked agammaglobulinemia.

Authors:  O Parolini; J Rohrer; L H Shapiro; M E Conley
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase.

Authors:  G M Dingjan; A Maas; M C Nawijn; L Smit; J S Voerman; F Grosveld; R W Hendriks
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

7.  Discordant phenotype in siblings with X-linked agammaglobulinemia.

Authors:  M J Bykowsky; R N Haire; Y Ohta; H Tang; S S Sung; E S Veksler; J M Greene; S M Fu; G W Litman; K E Sullivan
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

8.  Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.

Authors:  Jaya Rajaiya; Melissa Hatfield; Jamee C Nixon; David J Rawlings; Carol F Webb
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

10.  A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells.

Authors:  Bertrand Boisson; Yong-Dong Wang; Amma Bosompem; Cindy S Ma; Annick Lim; Tatiana Kochetkov; Stuart G Tangye; Jean-Laurent Casanova; Mary Ellen Conley
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.